Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement

  • Lassen M
  • Gallus A
  • Raskob G
  • et al.
754Citations
Citations of this article
334Readers
Mendeley users who have this article in their library.
Get full text

Abstract

There are various regimens for thromboprophylaxis after hip replacement. Low-molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to some degree. Orally active, specific factor Xa inhibitors such as apixaban may provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use.

Cite

CITATION STYLE

APA

Lassen, M. R., Gallus, A., Raskob, G. E., Pineo, G., Chen, D., & Ramirez, L. M. (2010). Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement. New England Journal of Medicine, 363(26), 2487–2498. https://doi.org/10.1056/nejmoa1006885

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free